期刊
INTERNATIONAL IMMUNOPHARMACOLOGY
卷 11, 期 11, 页码 1668-1679出版社
ELSEVIER
DOI: 10.1016/j.intimp.2011.08.002
关键词
Leishmaniasis; Anti-leishmanial; Immunomodulation; Chemotherapy
资金
- Indian Council of Medical Research (ICMR), Dept. of Science Technology
- Council of Scientific & Industrial Research CSIR, Govt. of India
- CSIR
- ICMR, Govt. of India
Leishmaniasis is caused by protozoan parasites of the genus Leishmania and causes a wide spectrum of clinical manifestations ranging from self-healing cutaneous lesions to the fatal visceral form. The use of pentavalent antimony, the mainstay of therapy of Leishmaniasis is now limited by its toxicity and alarming increase in unresponsiveness, especially in the Indian subcontinent. Furthermore, other anti-leishmanial drugs are unaffordable in many affected countries and as vaccination based approaches have not yet proved to be effective, chemotherapy remains the only alternative, emphasizing the need for identifying novel drug targets. In this review, we have described the different host immune signaling pathways that could be considered as potential drug targets for Leishmania chemotherapy. (C) 2011 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据